The panorama of familial hypercholesterolemia in Latin America: A systematic review

Journal of Lipid Research

Volumn 57, Issue 12, 2016, Pages 2115-2129

  Mehta, Roopa ^a   Zubirán, Rafael ^a   Martagón, Alexandro J ^b   Vazquez Cárdenas, Alejandra ^c   Segura Kato, Yayoi ^a,d   Tusié Luna, María Teresa ^a,d   Aguilar Salinas, Carlos A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Autosomal recessive hypercholesterolemia; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG; LDLR PROTEIN, HUMAN;

BRAZIL; COHORT ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENETICS; HEALTH CARE COST; HISPANIC; HUMAN; INDIGENOUS PEOPLE; MESTIZO; MEXICO; MORBIDITY; MORTALITY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW (TOPIC); HYPERLIPOPROTEINEMIA TYPE II; MUTATION; RISK FACTOR;

APOLIPOPROTEINS B; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LATIN AMERICA; MUTATION; RECEPTORS, LDL; RISK FACTORS;

EID: 85002744802     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R072231     Document Type: Review

References (117)

1. Singh, S., and V. Bittner. 2015. Familial hypercholesterolemia-epidemiology, diagnosis, and screening. Curr. Atheroscler. Rep. 17:482-485.
2. Najam, O., and K. Ray. 2015. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management. Cardiol. Ther. 4:25-38.
3. Benn, M., G. Watts, A. Tybjarg-Hansen, and B. Nordestgaard. 2016. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur. Heart J. 37:1384-1394.
4. Medeiros, A., A. Alves, and M. Bourbon. 2016. Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. Genet. Med. 18:316-324.
5. Nordestgaard, B., M. Chapman, S. Humphries, H. Ginsberg, L. Masana, O. Descamps, O. Wiklund, R. Hegele, F. Raal, J. Defesche, et al. 2013. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 34:3478-3490a.
6. Rynkiewicz, A., B. Cybulska, M. Banach, K. Filipiak, T. Guzik, B. Idzior-Walu., J. Imiela, P. Jankowski, L. Kosiewicz-Latoszek, J. Limon, et al. 2013. Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. J. Clin. Lipidol. 7:217-221.
7. Farnier, M., and E. Bruckert. 2012. Severe familial hypercholesterolaemia: current and future management. Arch. Cardiovasc. Dis. 105:656-665.
8. Vogt, A. 2015. The genetics of familial hypercholesterolemia and emerging therapies. Appl. Clin. Genet. 8:27-36.
9. Ito, M., and G. Watts. 2015. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs. 75:1715-1724.
10. Santos, R. 2016. Homozygous familial hypercholesterolemia: phenotype rules! Atherosclerosis. 248:252-254.
11. Bell, D. A., and G. F. Watts. 2016. Progress in the care of familial hypercholesterolemia: 2016. Med. J. Aust. 205:232-236.
12. Besseling, J., I. Kindt, M. Hof, J. Kastelein, B. Hutten, and G. Hovingh. 2014. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14, 000 mutation carriers. Atherosclerosis. 233:219-223.
13. Goldstein, J., W. Hazzard, H. Schrott, E. Bierman, and A. Motulsky. 1973. Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest. 52:1533-1543.
14. Genest, J., R. Hegele, J. Bergeron, J. Brophy, A. Carpentier, P. Couture, J. Davignon, R. Dufour, J. Frohlich, D. Gaudet, et al. 2014. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can. J. Cardiol. 30:1471-1481.
15. de Ferranti, S., A. Rodday, M. Mendelson, J. Wong, L. Leslie, and R. Sheldrick. 2016. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) clinical perspective. Circulation. 133:1067-1072.
16. Goldberg, A., and S. Gidding. 2016. Knowing the prevalence of familial hypercholesterolemia matters. Circulation. 133:1054-1057.
17. Moher, D., A. Liberati, J. Tetzlaff, and D. Altman. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6:e1000097.
18. Araujo, M., P. Botto, and C. Mazza. 2012. Uso de ezetimibe en el tratamiento de la hipercolesterolemia. An. Pediatr. (Barc.). 77:37-42.
19. Araujo, M. B., M. S. Pacce, M. Bravo, A. M. Pugliese, and C. Mazza. 2011. Severe hypercholesterolemia in children. Presentation of two cases and update of the literature. Arch. Argent. Pediatr. 109:e67. e71.
20. Ahualli, L., A. Stewart-Harris, G. Bastianelli, D. Radlovachki, A. Bartolome, P. Trigo, N. Cejas, G. Aballay Soteras, F. Duek, J. Lendoire, et al. 2007. Combined cardiohepatic transplantation due to severe heterozygous familial hypercholesteremia type II: first case in Argentina.a case report. Transplant. Proc. 39:2449-2453.
21. Figueiredo, M., J. Dos Santos, F. Alberto, and M. Zago. 1992. High frequency of the Lebanese allele of the LDLr gene among Brazilian patients with familial hypercholesterolaemia. J. Med. Genet. 29:813-815.
22. Alberto, F., M. Figueiredo, M. Zago, A. Araujo, and J. Dos-Santos. 1999. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Braz. J. Med. Biol. Res. 32:739-745.
23. van de Kerkhof, L., S. Van Eijk, J. Defesche, and J. Dos-Santos. 2003. Identification of a new mutation, S305C, in exon 7 of the low-density lipoprotein receptor gene in a Brazilian family with homozygous familial hypercholesterolemia. Genet. Test. 7:77-79.
24. Salazar, L., M. Hirata, S. Cavalli, E. Nakandakare, N. Forti, J. Diament, S. Giannini, M. Bertolami, and R. Hirata. 2002. Molecular basis of familial hypercholesterolemia in Brazil: identification of seven novel LDLR gene mutations. Hum. Mutat. 19:462-463.
25. Rocha, V., A. Chacra, W. Salgado, M. Miname, L. Turolla, A. Gagliardi, E. Ribeiro, R. Rocha, L. Avila, A. Pereira, et al. 2013. Extensive xanthomas and severe subclinical atherosclerosis in homozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 61:2193.
26. Barros, M., H. Ferreira-Fernandes, I. Barros, A. Barbosa, and G. Pinto. 2014. A case of severe carotid stenosis in a patient with familial hypercholesterolemia without significant coronary artery disease. Case Rep. Cardiol. 2014:853921.
27. Jannes, C., R. Santos, P. de Souza Silva, L. Turolla, A. Gagliardi, J. Marsiglia, A. Chacra, M. Miname, V. Rocha, W. Filho, et al. 2015. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis. 238:101-107.
28. Santos, R. 2014. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs? Atheroscler. Suppl. 15:19-25.
29. Pereira, C., M. Miname, M. Makdisse, R. Kalil Filho, and R. Santos. 2014. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq. Bras. Cardiol. 103:118-123.
30. Santos, R., A. Gagliardi, H. Xavier, A. Casella Filho, D. Araujo, F. Cesena, R. Alves, A. Pereira, A. Lottemberg, A. Chacra, et al. 2012. First Brazilian guidelines for familial hypercholesterolemia. Arq. Bras. Cardiol. 99:1-28.
31. Arteaga, Ll. A., M. A. Cuevas, R. A. Rigotti, F. Gonzalez, S. Castillo, L. P. Mata, and K. R. Alonso. 2007. Hipercolesterolemia familiar heterocigota: diagnostico molecular y terapia combinada. Caso clinico. Rev. Med. Chil. 135:216-220. Spanish.
32. Huijgen, R., A. Stork, J. Defeschea, J. Petera, R. Alonso, A. Cuevas, J. Kastelein, M. Durand, and E. Stroes. 2012. Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. Clin. Genet. 81:24-28.
33. Thiart, R., O. Loubser, J. de Villiers, M. Santos, and M. Kotze. 1997. Novel stop mutation causing familial hypercholesterolemia in a Costa Rican family. Mol. Cell. Probes. 11:457-458.
34. Kotze, M., R. Thiart, O. Loubser, J. de Villiers, M. Santos, M. Vargas, and A. Peeters. 1996. Mutation analysis reveals an insertional hotspot in exon 4 of the LDL receptor gene. Hum. Genet. 98:476-478.
35. Pereira, E., R. Ferreira, B. Hermelin, G. Thomas, C. Bernard, V. Bertrand, H. Nassiff, D. Del Castillo, G. Bereziat, and P. Benlian. 1995. Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana. Hum. Genet. 96:319-322.
36. Yu, L., E. Heere-Ress, B. Boucher, J. Defesche, J. Kastelein, M. Lavoie, and J. Genest, Jr. 1999. Familial hypercholesterolemia. Acceptor splice site (G-C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R (Honduras-1) [LDL-R1061 (-1) G-C]. Atherosclerosis. 146:125-131.
37. Canizales-Quinteros, S., C. Aguilar-Salinas, A. Huertas-Vazquez, M. Ordonez-Sanchez, M. Rodriguez-Torres, J. Venturas-Gallegos, L. Riba, S. Ramirez-Jimenez, R. Salas-Montiel, G. Medina-Palacios, et al. 2005. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia. Hum. Genet. 116:114-120.
38. Martinez, L., M. Ordonez Sanchez, R. Letona, V. Olvera Sumano, M. Miguel Guerra, M. Tusie-Luna, and C. Aguilar-Salinas. 2011. Hipercolesterolemia familiar homocigota por la mutacion c2271delT del gen del receptor LDL, detectada unicamente en mexicanos. Gac. Med. Mex. 147:525-527.
39. Magana Torres, M., S. Mora-Hernandez, N. Vazquez Cardenas, and A. Gonzalez Jaimes. 2014. Homozygous familial hypercholesterolemia: the c.1055G>A mutation in the LDLR gene and clinical heterogeneity. J. Clin. Lipidol. 8:525-527.
40. Vaca, G., A. Vazquez, M. Magana, M. Ramirez, I. Davalos, E. Martinez, B. Marin, and G. Carrillo. 2011. Mutational analysis of the LDL receptor and APOB genes in Mexican individuals with autosomal dominant hypercholesterolemia. Atherosclerosis. 218:391-396.
41. Aguilar-Salinas, C. 2001. Familial Hypercholesterolemia. Rev. Invest. Clin. 53:254-265.
42. Robles-Osorio, L., A. Huerta-Zepeda, M. L. Ordonez, S. Canizales-Quinteros, A. Diaz-Villasenor, R. Gutierrez-Aguilar, L. Riba, A. Huertas-Vazquez, M. Rodriguez-Torres, R. A. Gomez-Diaz, et al. 2006. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico. Arch. Med. Res. 37:102-108.
43. Robles-Osorio, L., M. L. Ordonez, C. A. Aguilar-Salinas, M. Auron-Gomez, M. T. Tusie-Luna, F. J. Gomez-Perez, and J. A. Rull-Rodrigo. 2003. Familial hypercholesterolemia due to liganddefective apolipoprotein B100: first case report in a Mexican family. Arch. Med. Res. 34:70-75.
44. Burgos, A., M. Aguilar, and K. de Arias. 2011. Visual vignette. Familial hypercholesterolemia. Endocr. Pract. 17:154.
45. Cefalu, A., G. Barraco, D. Noto, V. Valenti, C. Barbagallo, G. Elisir, L. Cuniberti, J. Werba, M. Libra, S. Costa, et al. 2006. Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. Int. J. Mol. Med. 17:539-546.
46. Esperon, P., V. Raggio, and M. Stoll. 2009. Una nueva mutacion en el promotor del gen del receptor de las lipoproteinas de baja densidad asociada a hipercolesterolemia familiar en homocigosis y heterocigosis. Clin. Investig. Arterioscler. 21:51-55.
47. Stoll, M., M. Lorenzo, V. Raggio, P. Esperon, and M. Zelarayan. 2011. Previniendo el infarto en el adulto joven: GENYCO, un registro nacional de hipercolesterolemia familiar. Revista Uruguaya Cardiologia. 26:16-26.
48. Esperon, P., V. Raggio, M. Lorenzo, and M. Stoll. 2013. Mutacion en el gen de la apolipoproteina B responsable de hipercolesterolemia familiar: primeros dos casos clinicos reportados en Uruguay. Revista Uruguaya de Cardiologia. 28:182-188.
49. Hobbs, H., M. Brown, and J. Goldstein. 1992. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:445-466.
50. Bertolini, S., S. Cassanelli, R. Garuti, M. Ghisellini, M. Simone, M. Rolleri, P. Masturzo, and S. Calandra. 1999. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 19:408-418.
51. Cenarro, A., H. Jensen, E. Casao, F. Civeira, J. Gonzalez-Bonillo, J. Rodriguez-Rey, N. Gregersen, and M. Pocovi. 1998. Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. Hum. Mutat. 11:413.
52. Leitersdorf, E., D. Van der Westhuyzen, G. Coetzee, and H. Hobbs. 1989. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J. Clin. Invest. 84:954-961.
53. Yu, W., A. Nohara, T. Higashikata, H. Lu, A. Inazu, and H. Mabuchi. 2002. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis. 165:335-342.
54. Yamamoto, T., C. Davis, M. Brown, W. Schneider, M. Casey, J. Goldstein, and D. Russell. 1984. The human LDL receptor: a cysteinerich protein with multiple Alu sequences in its mRNA. Cell. 39:27-38.
55. Dos Santos, J. 2003. Familial hypercholesterolemia in Brazil. Atheroscler. Suppl. 4:1-2.
56. Cohen, J., M. Kimmel, A. Polanski, and H. Hobbs. 2003. Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr. Opin. Lipidol. 14:121-127.
57. Bednarska-Makaruk, M., M. Bisko, M. Puawska, D. Hoffman-Zacharska, M. Rodo, M. Roszczynko, A. Solik-Tomassi, G. Broda, M. Polakowska, A. Pytlak, et al. 2001. Familial defective apolipoprotein B-100 in a group of hypercholesterolaemic patients in Poland. Identification of a new mutation Thr3492Ile in the apolipoprotein B gene. Eur. J. Hum. Genet. 9:836-842.
58. Palacios, L., L. Grandoso, N. Cuevas, E. Olano-Martin, A. Martinez, D. Tejedor, and M. Stef. 2012. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis. 221:137-142.
59. Ahmad, Z., B. Adams-Huet, C. Chen, and A. Garg. 2012. Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort. Circ Cardiovasc Genet. 5:666-675.
60. Farzadfar, F., M. Finucane, G. Danaei, P. Pelizzari, M. Cowan, C. Paciorek, G. Singh, J. Lin, G. Stevens, L. Riley, et al. 2011. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3'0 million participants. Lancet. 377:578-586.
61. Ballesteros, M. S., and B. Freidin. 2015. Reflections on the conceptualization and measurement of access to health services in Argentina: the case of the National Survey of Risk Factors 2009. Salud Colect. 11:523-535.
62. Malta, D. C., S. R. Stopa, B. P. Iser, R. T. Bernal, R. M. Claro, A. C. Nardi, A. A. Dos Reis, and C. A. Monteiro. 2015. Risk and protective factors for chronic diseases by telephone survey in capitals of Brazil, Vigitel 2014. Rev. Bras. Epidemiol. 18(Suppl 2):238-255.
63. Lotufo, P., R. Santos, R. Figueiredo, A. Pereira, J. Mill, S. Alvim, M. Fonseca, M. Almeida, M. Molina, D. Chor, et al. 2016. Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J. Clin. Lipidol. 10:568-576.
64. Cabrera, S., M. Alvo, J. S. Mindell, and C. Ferro. 2015. The National Health Survey of Chile gives useful information to health policy planning: analysis of diabetic nephropathy as an index of potential saving. Rev. Med. Chil. 143:679-681.
65. Freire, W. B., P. Belmont, D. F. López-Cevallos, and W. Waters. 2015. Ecuador's National Health and Nutrition Survey: objectives, design, and methods. Ann. Epidemiol. 25:877-878.
66. Jiménez-Corona, A., C. A. Aguilar-Salinas, R. Rojas-Martínez, and M. Hernández-Ávila. 2013. Type 2 diabetes and frequency of prevention and control measures. Salud Publica Mex. 55(Suppl 2):S137-S143.
67. Aguilar-Salinas, C., F. Gómez-Pérez, J. Rull, S. Villalpando, S. Barquera, and R. Rojas. 2010. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex. 52:S44-S53.
68. Gómez-Pérez, F., R. Rojas, S. Villalpando, S. Barquera, J. Rull, and C. Aguilar-Salinas. 2010. Prevention of cardiovascular disease based on lipid lowering treatment: a challenge for the Mexican health system. Salud Publica Mex. 52(Suppl 1):S54-S62.
69. Khera, A., H. Won, G. Peloso, K. Lawson, T. Bartz, X. Deng, E. van Leeuwen, P. Natarajan, C. Emdin, A. Bick, et al. 2016. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67:2578-2589.
70. Mabuchi, H., S. Miyamoto, K. Ueda, M. Oota, T. Takegoshi, T. Wakasugi, and R. Takeda. 1986. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis. 61:1-6.
71. 1991. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 303:893-896.
72. Mohrschladt, M., R. Westendorp, J. Gevers Leuven, and A. Smelt. 2004. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis. 172:329-335.
73. Mundal, L., M. Sarancic, L. Ose, P. Iversen, J. Borgan, M. Veierod, T. Leren, and K. Retterstol. 2014. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J. Am. Heart Assoc. 3:e001236.
74. Mata, N., R. Alonso, L. Badimón, T. Padró, F. Fuentes, O. Muñiz, F. Perez-Jiménez, J. López-Miranda, J. Díaz, J. Vidal, et al. 2011. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 10:94.
75. O'Brien, E., M. Roe, E. Fraulo, E. Peterson, C. Ballantyne, J. Genest, S. Gidding, E. Hammond, L. Hemphill, L. Hudgins, et al. 2014. Rationale and design of the familial hypercholesterolemia foundation cascade screening for awareness and detection of familial hypercholesterolemia registry. Am. Heart J. 167:342-349. e17.
76. Santos, R., T. Frauches, and A. Chacra. 2015. Cascade screening in familial hypercholesterolemia: advancing forward. J. Atheroscler. Thromb. 22:869-880.
77. Mundal, L., and K. Retterstl. 2016. A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries. Curr. Opin. Lipidol. 27:388-397.
78. 1999. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis. 142:105-112.
79. Krogh, H., L. Mundal, K. Holven, and K. Retterstøl. 2016. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur. Heart J. 37:1398-1405.
80. Alonso, R., N. Mata, S. Castillo, F. Fuentes, P. Saenz, O. Muñiz, J. Galiana, R. Figueras, J. Diaz, P. Gomez-Enterría, et al. 2008. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 200:315-321.
81. Versmissen, J., I. Botden, R. Huijgen, D. Oosterveer, J. Defesche, T. Heil, A. Muntz, J. Langendonk, A. Schinkel, J. Kastelein, et al. 2011. Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality. Atherosclerosis. 219:690-693.
82. Vallejo-Vaz, A., S. Kondapally Seshasai, D. Cole, G. Hovingh, J. Kastelein, P. Mata, F. Raal, R. Santos, H. Soran, G. Watts, et al. 2015. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 243:257-259.
83. Ned, R., and E. Sijbrands. 2011. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. 3: RRN1238.
84. DeMott, K., L. Nherera, EJ. Shaw, R. Minhas, SE. Humphries, M. Kathoria, G. Ritchie, V. Nunes, D. Davies, P. Lee, et al. 2008. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia.. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London.
85. Haralambos, K., P. Ashfield-Watt, and I. McDowell. 2016. Diagnostic scoring for familial hypercholesterolaemia in practice. Curr. Opin. Lipidol. 27:367-374.
86. 1991. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 303:893-896.
87. Williams, R., S. Hunt, M. Schumacher, R. Hegele, M. Leppert, E. Ludwig, and P. Hopkins. 1993. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72:171-176.
88. WHO Human Genetics Programme. 1999. Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. World Health Organization, Geneva. Accessed September 20, 2016, at http://www.who.int/iris/handle/10665/66346.
89. Haralambos, K., S. D. Whatley, R. Edwards, R. Gingell, D. Townsend, P. Ashfield-Watt, P. Lansberg, D. B. Datta, and I. F. McDowell. 2015. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis. 240:190-196.
90. Umans-Eckenhausen, M. A., J. C. Defesche, E. J. Sijbrands, R. L. Scheerder, and J. J. Kastelein. 2001. Review of first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet. 357:165-168.
91. Defesche, J. 2010. Defining the challenges of FH screening for familial hypercholesterolemia. J. Clin. Lipidol. 4:338-341.
92. Weng, S., J. Kai, H. Andrew Neil, S. Humphries, and N. Qureshi. 2015. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis. 238:336-343.
93. Sharifi, M., R. Rakhit, S. Humphries, and D. Nair. 2016. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart. 102:1003-1008.
94. Jacobson, T. A., M. K. Ito, K. C. Maki, C. E. Orringer, H. E. Bays, P. H. Jones, J. M. McKenney, S. M. Grundy, E. A. Gill, R. A. Wild, et al. 2014. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary. J. Clin. Lipidol. 8:473-488.
95. M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. L. Catapano, M. T. Cooney, U. Corrà, B. Cosyns, C. Deaton, et al. 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 252:207-274.
96. Watts, G., S. Gidding, A. Wierzbicki, P. Toth, R. Alonso, W. Brown, E. Bruckert, J. Defesche, K. Lin, M. Livingston, et al. 2014. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol. 171:309-325.
97. Vuorio, A., K. Docherty, S. Humphries, J. Kuoppala, and P. Kovanen. 2013. Statin treatment of children with familial hypercholesterolemia-trying to balance incomplete evidence of longterm safety and clinical accountability: Are we approaching a consensus? Atherosclerosis. 226:315-320.
98. Neil, A., J. Cooper, J. Betteridge, N. Capps, I. McDowell, P. Durrington, M. Seed, and S. Humphries. 2008. Reductions in allcause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 29:2625-2633.
99. Harada-Shiba, M., T. Sugisawa, H. Makino, M. Abe, M. Tsushima, Y. Yoshimasa, T. Yamashita, Y. Miyamoto, A. Yamamoto, H. Tomoike, et al. 2010. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 17:667-674.
100. Wong, B., G. Kruse, L. Kutikova, K. Ray, P. Mata, and E. Bruckert. 2016. Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature. Clin. Ther. 38:1696-1709.
101. 2010. FH Guideline Implementation Team Toolkit. Heart UK, West Berkshire, UK.
102. Gencera, B., and D. Nanchen. 2016. Identifying familial hypercholesterolemia in acute coronary syndrome. Curr. Opin. Lipidol. 27:375-381.
103. Pijlman, A. H., R. Huijgen, S. N. Verhagen, B. P. Imholz, A. H. Liam, J. J. Kastelein, E. J. Abbink, A. F. Stalenhoef, and F. L. Visseren. 2010. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 209:189-194.
104. deGoma, E., Z. Ahmad, E. O'Brien, I. Kindt, P. Shrader, C. Newman, Y. Pokharel, S. Baum, L. Hemphill, L. Hudgins, et al. 2016. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States. Circ Cardiovasc Genet. 9:240-249.
105. Thompson, G. 2008. Recommendations for the use of LDL apheresis. Atherosclerosis. 198:247-255.
106. Gidding, S., M. Ann Champagne, S. de Ferranti, J. Defesche, M. Ito, J. Knowles, B. McCrindle, F. Raal, D. Rader, R. Santos, et al. 2015. The agenda for familial hypercholesterolemia. Circulation. 132:2167-2192.
107. Santos, R., S. Gidding, R. Hegele, M. Cuchel, P. Barter, G. Watts, S. Baum, A. Catapano, M. Chapman, J. Defesche, et al. 2016. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 4:850-861.
108. González, C. A., A. Pavía, F. J. Redding, J. L. Zacarías, M. A. Ramírez, M. Alpízar, J. Aspe, J. Carranza, R. Barba, J. C. Ramírez, et al. 2009. Encuesta sobre el manejo de dislipidemia con estatinas en México: Porcentaje de pacientes que alcanzan las metas establecidas por el Programa Nacional de Educación en Colesterol (National Cholesterol Education Program [NCEP]). Rev Mex Cardiol. 20:18-22.
109. Homedes, N., and A. Ugalde. 2015. Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Bull. World Health Organ. 93:674-683.
110. Prüss-Üstün A., C. Mathers, C. Corvalán, and A. Woodward. 2003. Introduction and methods: assessing the environmental burden of disease at national and local levels.. WHO Environmental Burden of Disease Series, No. 1. World Health Organization, Geneva, Switzerland.
111. Nherera, L., D. Marks, R. Minhas, M. Thorogood, and S. Humphries. 2011. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 97:1175-1181.
112. Bruckert, E., S. Saheb, J. Bonté, and C. Coudray-Omnès. 2014. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey. Atheroscler. Suppl. 15:46-51.
113. Mata, N., R. Alonso, J. Banegas, D. Zambon, A. Brea, and P. Mata. 2014. Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe. Eur. J. Public Health. 24:221-225.
114. Ågård, A., I. Bolmsjö, G. Hermerén, and J. Wahlstöm. 2005. Familial hypercholesterolemia: ethical, practical and psychological problems from the perspective of patients. Patient Educ. Couns. 57:162-167.
115. Mortensen, G. L., I. B. Madsen, C. Kruse, and H. Bundgaard. 2016. Familial hypercholesterolaemia reduces the quality of life of patients not reaching treatment targets. Dan. Med. J. 63:A5224.
116. Merchán, A., A. J. Ruiz, R. Campo, C. E. Prada, J. M. Toro, R. Sánchez, J. E. Gómez, N. I. Jaramillo, D. I. Molina, H. Vargas-Uricoechea, et al. 2016. Hipercolesterolemia familiar: artículo de revisión. Rev. Colomb. Cardiol. 23(S4):4-26.
117. Watts, G., D. Sullivan, N. Poplawski, F. van Bockxmeer, I. Hamilton-Craig, P. Clifton, R. O'Brien, W. Bishop, P. George, P. Barter, et al. 2011. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler. Suppl. 12:221-263.